BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
Brainstorm Cell Therapeutics(US:BCLI) Prnewswire·2025-03-26 12:15NEW YORK, March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30, 2025, to regain compliance with certain continued listing standards of The Nasdaq Capital Market.BrainStorm p ...